Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis

Inclusion Criteria: * Patient with cystic fibrosis confirmed by sweat or genetic test * Patient with clinical signs of exacerbation (increased cough, sputum (abundance, purulence), fever, anorexia, weight loss and FEV1) or acute exacerbations (defined at the clinician's discretion ) * FEV1 ≥ 25% * Pseudomonas aeruginosa chronic carriers (defined by at least two antipyocyanic precipitation arcs or at least 3 successive positive ECBCs over a period of 18 months) * Patient who received at least 1 IV course of antibiotics in the 18 months prior to inclusion. Exclusion Criteria: * Severe exacerbation (requiring hospitalization due to severe amputation of FEV 1, oxygen deficiency, or severe impairment of general health). * Patient with 3rd antibiotic therapy (triple therapy) * Patient colonized in Burkholderia cepacia * Patient colonized by an atypical mycobacterium * Patient with pulmonary transplant or transplant * chronic tinnitus * patient using hearing aid * Hypersensitivity to tobramycin and other antibiotics of the aminoglycoside family * Cirrhosis of Grades B and C according to the Child-Pugh Classification * Myasthenia gravis * Simultaneous administration of another aminoglycoside * Renal failure * Recent history of severe hemoptysis (within 2 months before inclusion) * Patient participating simultaneously in another clinical study conducted on a drug for the duration of its participation in this research